General Electrics' GE Healthcare division is set for some major growth in India. Revenues in the country will grow from $570 million now to $1 billion within four years, an executive said.
GE Healthcare has gotten FDA approval for its plant in Oslo, Norway, to make a heart imaging agent. The company said that with approval, it will be the only contrast media manufacturer to supply its own stock to the U.S.
CareFusion is handing over $500 million for GE Healthcare's Vital Signs arm, an acquisition it said will make it a giant in the respiratory and anesthesia consumables business but also fuel a broader global expansion.
The FDA has approved the second imaging agent that can be used to detect a toxic protein found clustered in the fogged brains of Alzheimer's patients, but there's no guarantee it will ever find much of a market.
GE Healthcare has at long last nailed down FDA approval for an imaging agent designed to help evaluate living patients for Alzheimer's disease or dementia. It's the second brain-imaging drug of its kind to gain U.S. regulators' OK, and plans call for rolling it out commercially in 2014.
GE Healthcare has gained FDA approval for an imaging agent designed to help evaluate patients for Alzheimer's disease or dementia. Regulators announced the approval, which designates flutemetamol--now called Vizamyl--as a "radioactive diagnostic drug" for use in PET imaging of the brain in adults being scrutinized for either condition.
The FDA slapped GE Healthcare's recall of a number of ventilator and anesthesia machines with a Class I status--its most serious designation.
GE Healthcare will help test whether imaging neuroinflammation in MS patients before and after they take Biogen Idec's Tysabri can spot patients who will respond best to the drug. Also backing the clinical study: Fast Forward, a non-profit subsidiary of the National Multiple Sclerosis Society.
The Centers for Medicare and Medicaid Services sees little benefit in using PET scans to detect beta-amyloid buildups in dementia patients, and the agency has declined to cover the procedure as a diagnostic, a blow to companies like GE Healthcare, Eli Lilly and Navidea.
GE Healthcare will use its gene sequencing expertise with a group at Sweden's Karolinska Institutet to find causes of metastatic breast cancer.